COMMUNIQUÉS West-GlobeNewswire
 
      -   
  AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board28/10/2025
-   
  Tonix Pharmaceuticals Announces Presentation at BIO-Europe 202528/10/2025
-   
  Zag Bio™ Launches with $80 Million Financing to Advance Thymus-targeted Medicines for Autoimmune Diseases28/10/2025
-   
  Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 202528/10/2025
-   
  Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 202528/10/2025
-   
  Verano Holdings Corp. Announces Shareholder Approval to Redomicile Parent Company from British Columbia to Nevada28/10/2025
-   
  Castle Biosciences to Participate in Upcoming Investor Conferences28/10/2025
-   
  Entrada Therapeutics to Present at Upcoming Investor Conferences28/10/2025
-   
  Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market28/10/2025
-   
  ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD28/10/2025
-   
  Causeway Therapeutics Debuts Positive Data from Phase 2 Clinical Trial of TenoMiR® for Lateral Epicondylitis28/10/2025
-   
  Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 202528/10/2025
-   
  Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID28/10/2025
-   
  Cronos Brings Back Popular, Limited-Edition Spinach® Green Apple-Flavored Products for the Fall Season28/10/2025
-   
  TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI28/10/2025
-   
  Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance28/10/2025
-   
  Context Therapeutics to Participate in Upcoming Investor Conferences28/10/2025
-   
  Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution28/10/2025
-   
  Evidence Against Evidence: CERN-IEEE FPGA vs. Crosetto 3D-Flow, a Breakthrough Invention Recognized 32 Years Ago That Could Have, and Can Still, Save Billions of Euros and Millions of Lives28/10/2025
Pages